anti-inflammatory agent

Isoxepac (Olopatadine USP Related Compound C) is a non-steroidal anti-antiphlogistic agent and analgesic.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Compound 2g (Anti-inflammatory agent 93) is an active compound that exhibits analgesic activity.

Anti-inflammatory agent 94 (compound 4b) is an effective cannabinoid ligand with Ki values of 29 nM for CB2 and 8 nM for CB1. It is applicable in inflammation research.

Anti-inflammatory agent 95 (Compound 2e) is a compound with potent anti-inflammatory properties, showing significant inhibition of NO production in LPS-induced RAW 264.7 mouse macrophages, with an IC50 of 8.8 μM. It also effectively suppresses the secretion of TNF-α and IL-1β, achieving inhibition rates of 60% and greater than 90% at 100 μM, respectively. Anti-inflammatory agent 95 holds promise for research into inflammatory diseases.

Anti-inflammatory agent 96 (Compound 5) is a potent anti-inflammatory compound. It effectively reduces ear edema induced by TPA and paw edema caused by CFA.

Anti-inflammatory agent 97 (Compound 1l) is an anti-inflammatory compound and also inhibits oxidative stress. It can reduce colon shortening and alleviate inflammatory symptoms in a mouse model of ulcerative colitis induced by DSS. Additionally, it modulates the inflammation-associated TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway.

Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory compound. It inhibits the MAPK and NF-κB signaling pathways by preventing the phosphorylation of IκB-α and blocking the nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 also reduces the production of NO (IC50: 0.5 μM) and the secretion of TNF-α, IL-6, and IL-1β.

Anti-inflammatory agent 102 (Compound 11a) is an orally effective anti-inflammatory compound. It exerts its effects by inhibiting the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. This agent displays significant anti-inflammatory activity by suppressing the release of NO, ROS, and inflammatory cytokines such as IL-6, TNF-α, and IL-1β. Anti-inflammatory agent 102 is applicable in research concerning inflammatory diseases, including ulcerative colitis (UC).

Anti-inflammatory agent 101 (Compound C04) is an orally active anti-inflammatory agent with notable anti-lipid accumulation, anti-inflammatory, and anti-fibrotic properties. It functions by reducing fatty acid uptake, enhancing fatty acid oxidation, and alleviating inflammation, making it applicable in the study of NASH and related liver fibrosis.

Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory properties. It inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice.

Anti-inflammatory agent 74 (B5) is known for its ability to inhibit NO, IL-6, and TNF-α, with IC50 values of 10.88 μM and 4.93 μM for NO and IL-6, respectively. It alleviates acute lung injury (ALI) by modulating inflammatory mediators and inhibiting the MAPK and NF-κB signaling pathways.

Anti-inflammatory agent 71 (Compound 3.2) is an anti-inflammatory compound that reduces levels of neutrophils, COX-2, nitrotyrosine, IL-1b, and C-reactive protein, while increasing eNOS levels.

Anti-inflammatory agent 72 (compound 5) is a novel resveratrol derivative hybridized with benzoyl hydrazone. It exhibits both anti-inflammatory and antioxidant activities by activating Nrf2 and inhibiting the NF-κBp65/iNOS and MAPKs signaling pathways.

Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor targeting Carbonic Anhydrase and COX-2, and is a sulfonamide derivative of Polmacoxib. It exhibits anti-inflammatory and analgesic properties. The IC50 values for COX-1 and COX-2 are 10.4 μM and 50 nM, respectively. The Ki values for binding to various Carbonic Anhydrase isoforms are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII).

Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor that targets Carbonic Anhydrase and COX-2, and is a sulfonamide derivative of Polmacoxib, exhibiting anti-inflammatory and analgesic properties. The IC50 values of Anti-inflammatory agent 68 for COX-1 and COX-2 are 12.6 μM and 60 nM, respectively. It binds to different Carbonic Anhydrase isoforms with Ki values of 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII).

Anti-inflammatory agent 77 (C12) is a β-cyclopentenedione-derived monocarbonyl curcumin analog and acts as an inhibitor of interleukin-6 (IL-6). It is applicable in research related to wound healing.

Anti-inflammatory agent 76 (Compd 8b) is an anti-inflammatory compound with notable inhibition activities on NO, IL-1β, and IL-6.

Anti-inflammatory agent 84 (Compound 4D) is a coumarin derivative with notable antibacterial and anti-inflammatory properties. It inhibits E. coli, Candida albicans, Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA) with MIC values of 312, 156, 19, and 316 µg/mL, respectively. Additionally, it suppresses biofilm formation of S. aureus, E. coli, and MRSA, with IC50 values of 185, 321, and 99 µM, respectively. Anti-inflammatory agent 84 also reduces nitric oxide production in lipopolysaccharide-stimulated RAW264.7 macrophages.

Anti-inflammatory agent 78 (compound L-37) is a potent anti-inflammatory agent. It effectively inhibits PGE2, PGE1, COX-2, and COX-1. Additionally, Anti-inflammatory agent 78 suppresses the release of NO in LPS-stimulated RAW 264.7 cell lines.

Anti-inflammatory agent 79 (compound 17q) is an isoquinolinone derivative-based HIF-1 inhibitor (IC50: 0.55 μM), effectively blocking HIF-1 signaling and promoting the degradation of HIF-1α. It inhibits synovial invasion and migration, as well as angiogenesis. In mouse inflammation models, Anti-inflammatory agent 79 effectively reduces foot swelling and arthritis and lowers levels of inflammatory factors and angiogenesis in vivo.

Anti-inflammatory agent 86 is a derivative of Chrysin with anti-inflammatory properties. It inhibits TNF-α-induced monocyte adhesion to colon epithelium, with an IC50 of 4.71 μM. Anti-inflammatory agent 86 shows potential for use in inflammatory bowel disease (IBD) research.

Anti-inflammatory agent 88 (compound 6) is a carbazole derivative found in marine Streptomyces with anti-inflammatory properties. It exerts its effects by inhibiting pro-inflammatory factors and enhancing the expression of anti-inflammatory factors within the Myd88/Nf-κB pathway. This compound holds potential for the development of anti-inflammatory drugs.

Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. It inhibits TNF-α synthesis and release in the U937 human macrophage cell line with an IC50 of 0.024 nM. Additionally, Anti-inflammatory agent 104 reduces eosinophil levels in rat lungs by 63%.